|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dudley B and Brand RE: Pancreatic cancer
surveillance: Who, when, and how. Curr Treat Options Gastroenterol.
17:681–691. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Horowitz M, Neeman E, Sharon E and
Ben-Eliyahu S: Exploiting the critical perioperative period to
improve long-term cancer outcomes. Nat Rev Clin Oncol. 12:213–226.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Aguirre JA, Lucchinetti E, Clanachan AS,
Plane F and Zaugg M: Unraveling interactions between anesthetics
and the endothelium: Update and novel insights. Anesth Analg.
122:330–348. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yap A, Lopez-Olivo MA, Dubowitz J, Hiller
J and Riedel B; Global Onco-Anesthesia Research Collaboration
Group, : In reply: Comment on ‘Anesthetic technique and cancer
outcomes: A meta-analysis of total intravenous versus volatile
anesthesia’. Can J Anaesth. 67:152–153. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kelly K, Hutchinson G, Nebenius-Oosthuizen
D, Smith AJ, Bartsch JW, Horiuchi K, Rittger A, Manova K, Docherty
AJ and Blobel CP: Metalloprotease-disintegrin ADAM8: Expression
analysis and targeted deletion in mice. Dev Dyn. 232:221–231. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schlomann U, Rathke-Hartlieb S, Yamamoto
S, Jockusch H and Bartsch JW: Tumor necrosis factor alpha induces a
metalloprotease-disintegrin, ADAM8 (CD 156): Implications for
neuron-glia interactions during neurodegeneration. J Neurosci.
20:7964–7971. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schlomann U, Wildeboer D, Webster A,
Antropova O, Zeuschner D, Knight CG, Docherty AJ, Lambert M,
Skelton L, Jockusch H, et al: The metalloprotease disintegrin
ADAM8. Processing by autocatalysis is required for proteolytic
activity and cell adhesion. J Biol Chem. 277:48210–48219. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gao Y, Yu X, Zhang F and Dai J: Propofol
inhibits pancreatic cancer progress under hypoxia via ADAM8. J
Hepatobiliary Pancreat Sci. 26:219–226. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu X, Shi J, Wang X and Zhang F: Propofol
affects the growth and metastasis of pancreatic cancer via ADAM8.
Pharmacol Rep. 72:418–426. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Safe S, Imanirad P, Sreevalsan S, Nair V
and Jutooru I: Transcription factor Sp1, also known as specificity
protein 1 as a therapeutic target. Expert Opin Ther Targets.
18:759–769. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kang Y, Nagaraja AS, Armaiz-Pena GN,
Dorniak PL, Hu W, Rupaimoole R, Liu T, Gharpure KM, Previs RA,
Hansen JM, et al: Adrenergic stimulation of DUSP1 impairs
chemotherapy response in ovarian cancer. Clin Cancer Res.
22:1713–1724. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li X, Fu Y, Xia X, Zhang X, Xiao K, Zhuang
X and Zhang Y: Knockdown of SP1/Syncytin1 axis inhibits the
proliferation and metastasis through the AKT and ERK1/2 signaling
pathways in non-small cell lung cancer. Cancer Med. 8:5750–5759.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang S, Zhen L, Liu Z, Ai Q, Ji Y, Du G,
Wang Y and Bu Y: Identification and analysis of the promoter region
of the human HAS3 gene. Biochem Biophys Res Commun. 460:1008–1014.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vlieghe D, Sandelin A, De Bleser PJ,
Vleminckx K, Wasserman WW, van Roy F and Lenhard B: A new
generation of JASPAR, the open-access repository for transcription
factor binding site profiles. Nucleic Acids Res. 34:D95–D97. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu X, Gao Y and Zhang F: Propofol inhibits
pancreatic cancer proliferation and metastasis by up-regulating
miR-328 and down-regulating ADAM8. Basic Clin Pharmacol Toxicol.
125:271–278. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xiao Y, Yurievich UA and Yosypovych SV:
Long noncoding RNA XIST is a prognostic factor in colorectal cancer
and inhibits 5-fluorouracil-induced cell cytotoxicity through
promoting thymidylate synthase expression. Oncotarget.
8:83171–83182. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Meng C, Song L, Wang J, Li D, Liu Y and
Cui X: Propofol induces proliferation partially via downregulation
of p53 protein and promotes migration via activation of the Nrf2
pathway in human breast cancer cell line MDA-MB-231. Oncol Rep.
37:841–848. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ou W, Lv J, Zou X, Yao Y, Wu J, Yang J,
Wang Z and Ma Y: Propofol inhibits hepatocellular carcinoma growth
and invasion through the HMGA2-mediated Wnt/β-catenin pathway. Exp
Ther Med. 13:2501–2506. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ecimovic P, Murray D, Doran P and Buggy
DJ: Propofol and bupivacaine in breast cancer cell function in
vitro - role of the NET1 gene. Anticancer Res. 34:1321–1331.
2014.PubMed/NCBI
|
|
22
|
Cui WY, Liu Y, Zhu YQ, Song T and Wang QS:
Propofol induces endoplasmic reticulum (ER) stress and apoptosis in
lung cancer cell H460. Tumour Biol. 35:5213–5217. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li H, Lu Y, Pang Y, Li M, Cheng X and Chen
J: Propofol enhances the cisplatin-induced apoptosis on cervical
cancer cells via EGFR/JAK2/STAT3 pathway. Biomed Pharmacother.
86:324–333. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Romagnoli M, Mineva ND, Polmear M, Conrad
C, Srinivasan S, Loussouarn D, Barillé-Nion S, Georgakoudi I, Dagg
Á, McDermott EW, et al: ADAM8 expression in invasive breast cancer
promotes tumor dissemination and metastasis. EMBO Mol Med.
6:278–294. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ishikawa N, Daigo Y, Yasui W, Inai K,
Nishimura H, Tsuchiya E, Kohno N and Nakamura Y: ADAM8 as a novel
serological and histochemical marker for lung cancer. Clin Cancer
Res. 10:8363–8370. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schlomann U, Koller G, Conrad C, Ferdous
T, Golfi P, Garcia AM, Höfling S, Parsons M, Costa P, Soper R, et
al: ADAM8 as a drug target in pancreatic cancer. Nat Commun.
6:61752015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Conrad C, Benzel J, Dorzweiler K, Cook L,
Schlomann U, Zarbock A, Slater EP, Nimsky C and Bartsch JW: ADAM8
in invasive cancers: Links to tumor progression, metastasis, and
chemoresistance. Clin Sci (Lond). 133:83–99. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cao L, Yao Y, Lee V, Kiani C, Spaner D,
Lin Z, Zhang Y, Adams ME and Yang BB: Epidermal growth factor
induces cell cycle arrest and apoptosis of squamous carcinoma cells
through reduction of cell adhesion. J Cell Biochem. 77:569–583.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nagaoka M, Shiraishi Y and Sugiura Y:
Selected base sequence outside the target binding site of zinc
finger protein Sp1. Nucleic Acids Res. 29:4920–4929. 2001.
View Article : Google Scholar : PubMed/NCBI
|
